Citi Starts Xenon Pharmaceuticals (XENE) at Buy, 'Best-In-Class Epilepsy Asset XEN1101 Offers Additional Upside in MDD'
Tweet Send to a Friend
(Updated - January 3, 2024 4:14 PM EST)
Citi analyst David Hoang initiates coverage on Xenon Pharmaceuticals (NASDAQ: XENE) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Citi analyst David Hoang initiates coverage on Xenon Pharmaceuticals (NASDAQ: XENE) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
